Opinion
Video
Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When asked what the ideal patient is for the 4-drug combination of lenalidomide, bortezomib, and dexamethasone plus daratumumab, Fonseca responded that is the wrong question; rather, clinicians should consider if there are any patients who should not receive this regimen.
Minimal residual disease (MRD) testing has become central to myeloma treatment goals. As the most sensitive test for residual disease, MRD negativity is now the most important prognostic factor in myeloma. Four analyses support the predictive value of MRD status. Unknowns remain regarding discontinuing therapy with sustained MRD negativity and escalating therapy for persistent MRD positivity, although Fonseca tests patients routinely after transplant to guide next treatment steps aimed at achieving MRD negativity. While this must be done judiciously, he believes eliminating every myeloma cell should be the primary goal.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
